What question did this study set out to answer?

To evaluate whether prostate-specific antigen (PSA) screening reduces direct prostate cancer treatment costs in a real-world community screening setting.

August 19, 2026Expert Review of Pharmacoeconomics & Outcomes Research

The economic impact of opportunistic PSA screening: a real-world cost analysis from China amid evolving policy landscape

View Full Paper

Ask AI

Bookmark

Authors

ZLZhehan Lin WLWei Li PHPengcheng Hu

Discussion

Member takes

Overview

Propensity score-matched study reveals a 44% reduction in direct medical costs among screening-detected prostate cancer patients, supporting the economic case for organized PSA screening.

Key Points

To evaluate whether prostate-specific antigen (PSA) screening reduces direct prostate cancer treatment costs in a real-world community screening setting.
Conducted a propensity score-matched analysis comparing 61 screening-detected prostate cancer patients with 61 symptom-detected controls diagnosed and treated at a single central hospital in China.
Assessed total direct medical expenditures across examinations, hospital stays, surgical interventions, chemotherapy, and radiotherapy.
Direct medical treatment costs were significantly lower in the screening-detected cohort, showing a 44% reduction compared to symptom-detected controls (p = 0.0163).
Cost reductions were linked to earlier-stage diagnosis, which enabled less intensive therapeutic interventions.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a858aaf03308d306e2d7ec7 https://doi.org/10.1080/14737167.2026.2717281

View Full Paper

Ask AI

Bookmark

August 19, 2026Expert Review of Pharmacoeconomics & Outcomes Research

The economic impact of opportunistic PSA screening: a real-world cost analysis from China amid evolving policy landscape

View Full Paper

Ask AI

Bookmark

Authors

ZLZhehan Lin WLWei Li PHPengcheng Hu

Discussion

Member takes

Overview

Propensity score-matched study reveals a 44% reduction in direct medical costs among screening-detected prostate cancer patients, supporting the economic case for organized PSA screening.

Key Points

To evaluate whether prostate-specific antigen (PSA) screening reduces direct prostate cancer treatment costs in a real-world community screening setting.
Conducted a propensity score-matched analysis comparing 61 screening-detected prostate cancer patients with 61 symptom-detected controls diagnosed and treated at a single central hospital in China.
Assessed total direct medical expenditures across examinations, hospital stays, surgical interventions, chemotherapy, and radiotherapy.
Direct medical treatment costs were significantly lower in the screening-detected cohort, showing a 44% reduction compared to symptom-detected controls (p = 0.0163).
Cost reductions were linked to earlier-stage diagnosis, which enabled less intensive therapeutic interventions.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a858aaf03308d306e2d7ec7 https://doi.org/10.1080/14737167.2026.2717281

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark